A5049475918- Chronic Lymphocytic Leukemia Research
- Food Allergy and Anaphylaxis Research
- Immune Cell Function and Interaction
- Lymphoma Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Allergic Rhinitis and Sensitization
- Chronic Myeloid Leukemia Treatments
- Acute Lymphoblastic Leukemia research
- PI3K/AKT/mTOR signaling in cancer
- Urticaria and Related Conditions
- Contact Dermatitis and Allergies
- T-cell and Retrovirus Studies
- Eosinophilic Esophagitis
- Multiple Myeloma Research and Treatments
- Mast cells and histamine
- Protein Degradation and Inhibitors
- CAR-T cell therapy research
- Polyomavirus and related diseases
- Food Safety and Hygiene
University of Chicago
2020
The Ohio State University
2007-2016
The immunomodulatory drug lenalidomide has demonstrated efficacy in patients with chronic lymphocytic leukemia (CLL), despite a lack of direct cytotoxic effects vitro mechanism vivo is thought to occur via combination enhanced immune activity and an alteration tumor cell-microenvironment interactions. We demonstrate whole blood from CLL that significantly depletes malignant B cells. Lenalidomide also induced production interleukin-21 (IL21) its mRNA T cells CLL. In addition, upregulation...
In recent decades, immunoglobulin E (IgE) mediated food allergy has become a growing public health concern. Converging evidence from cross-sectional prevalence studies, care utilization records, and cohort studies indicate that allergies are increasingly prevalent often severe. Although IgE-mediated long been considered predominantly pediatric concern, analysis of self-reported data suggests may be more among adult populations than previously acknowledged, with many reported cases...
CpG oligodeoxynucleotides (ODNs) upregulate the interleukin-21 receptor (IL21R) and enhance IL-21-mediated cytotoxicity in chronic lymphocytic leukemia (CLL) B cells. We demonstrate that treatment of CLL cells with ODN CpG-685 leads to increased IL21R expression, this expression enhances effects IL-21 as evidenced by phosphorylation JAK1, STAT1, STAT3, compared without prior stimulation. Induction also enhanced cytotoxicity. The mechanism which ODNs has not been elucidated, although...
Abstract Interleukin-21 (IL-21) is an immunomodulatory cytokine with cytotoxic activity against chronic lymphocytic leukemia (CLL) B cells. Its has been shown in part to directly correlate level of surface expression the IL-21 receptor (IL-21R) on CLL Although CpG and CD40 ligand have show induce upregulation IL-21R, their limited availability for clinical use prompted us investigate alternative agents such as lenalidomide. We observed that treatment cells 0.5 μM lenalidomide upregulated...
<div>Abstract<p>The immunomodulatory drug lenalidomide has demonstrated efficacy in patients with chronic lymphocytic leukemia (CLL), despite a lack of direct cytotoxic effects <i>in vitro</i>. The mechanism vivo</i> is thought to occur via combination enhanced immune activity and an alteration tumor cell–microenvironment interactions. We demonstrate whole blood from CLL that significantly depletes malignant B cells. Lenalidomide also induced production...
<div>Abstract<p>The immunomodulatory drug lenalidomide has demonstrated efficacy in patients with chronic lymphocytic leukemia (CLL), despite a lack of direct cytotoxic effects <i>in vitro</i>. The mechanism vivo</i> is thought to occur via combination enhanced immune activity and an alteration tumor cell–microenvironment interactions. We demonstrate whole blood from CLL that significantly depletes malignant B cells. Lenalidomide also induced production...